Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a multisystemic autosomal recessive disease due to primary thymidine phosphorylase (TP) deficiency. To restore TP activity, we performed reduced intensity allogeneic stem cell transplantations (alloSCTs) in two patients. In the first, alloSCT failed to engraft, but the second achieved mixed donor chimerism, which partially restored buffy coat TP activity and lowered plasma nucleosides. Thus, alloSCT can correct biochemical abnormalities in the blood of patients with MNGIE, but clinical efficacy remains unproven.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Treating MNGIE
- Shamima Rahman, University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK[email protected]
- Iain P Hargreaves
Submitted February 01, 2007 - Reply from the Authors
- Michio Hirano, Columbia University Med. Center, 630 West 168th Street, P&S 4-443, New York, NY 10032[email protected]
- Ramon A. Martí, and Salvatore DiMauro
Submitted February 01, 2007 - Reply from the editorialists
- Patrick F. Chinnery, Mitochondrial Research Group and Institute of Human Genetics, Newcastle Univeristy, M4014, The Medical School, Framlinton Place, Newcastle upon Tyne, NE2 4HH, UK[email protected]
- John Vissing
Submitted February 01, 2007
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Brief Communications
Infusion of platelets transiently reduces nucleoside overload in MNGIEM. C. Lara, B. Weiss, I. Illa et al.Neurology, September 13, 2006 -
Editorials
Treating MNGIEIs reducing blood nucleosides the first cure for a mitochondrial disorder?Patrick F. Chinnery, John Vissing et al.Neurology, October 23, 2006 -
Clinical/Scientific Notes
CARRIER ERYTHROCYTE ENTRAPPED THYMIDINE PHOSPHORYLASE THERAPY FOR MNGIEN. F. Moran, M. D. Bain, M.M.K. Muqit et al.Neurology, August 25, 2008 -
Clinical/Scientific Notes
Clinical and biochemical improvements in a patient with MNGIE following enzyme replacementBridget E. Bax, Murray D. Bain, Mauro Scarpelli et al.Neurology, August 21, 2013